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treatment through time using repeated measures ANCOVA.
RESULTS: The SIS was found to meet psychometric standards
for a valid questionnaire in a GAD population. The efﬁcacy
analysis found four domains (Daily Activities, Emotional Impact,
Energy/Fatigue and Satisfaction with Sleep) consistently demon-
strated signiﬁcantly greater improvements in the zolpidem tar-
trate extended-release group at each timepoint. A quick onset of
treatment effect was evident in all domains of the SIS by Week 2,
with all domains statistically signiﬁcantly demonstrating greater
improvement than placebo. Longitudinal analyses found all SIS
domains to be statistically signiﬁcantly superior to placebo.
CONCLUSION: The SIS adequately meets the criteria for a
validated measure to be used in GAD. The SIS was responsive to
treatment effects in this clinical trial and able to demonstrate
improvements in patient reported outcomes, favoring zolpidem
tartrate extended-release.
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OBJECTIVES: Prior to use in an international study, the Hos-
pital Anxiety and Depression Scale (HADS) underwent linguis-
tic validation in 30 languages. The original scale was developed
in UK English to detect states of anxiety and depression in and
outside hospital and also community settings. A rigorous meth-
odology was required to ensure conceptual equivalence and cul-
tural relevance across different languages. METHODS: The
translation process was conducted by a specialist in each target
country using the following standardized methodology: 1) two
forward translations by professional translators who were
native speakers of the target language and ﬂuent in English; 2)
comparison and reconciliation of the translations by the spe-
cialist in the target country; 3) backward translation by a
native English speaker; 4) comparison of source and backward
version; and 5) review by the developer. The linguistic valida-
tion methodology for some languages deviated slightly from
what is described above, as a translation already existed; the
translation process started at the backward translation step on
the existing version. RESULTS: The translation process
revealed linguistic and conceptual challenges. Translating idi-
omatic expressions often required paraphrasing to convey the
intended meaning whenever a literal equivalent was not con-
ceptually equivalent and culturally relevant. In addition, while
in most language versions it was possible to retain the same
tense as in the original instrument without alteration of
meaning in a few translations it proved necessary to use a dif-
ferent tense to achieve clarity and equivalence of concept.
CONCLUSION: The language versions of the HADS were
established according to a rigorous translation methodology.
The process aims to ensure conceptual equivalence across dif-
ferent language versions to facilitate international comparison
and pooling of data. The linguistic validation process as
a whole supports the advantage of integrating international
feedback on concepts and wording before a questionnaire is
ﬁnalized.
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OBJECTIVES: To evaluate cost-effectiveness of escitalopram
vs. duloxetine in MDD and to identify key drivers of costs in
treatment of depression with escitalopram and duloxetine.
METHODS: An economic evaluation was conducted alongside a
double-blind, randomized study (escitalopram 20 mg/day and
duloxetine 60 mg/day) in outpatients with MDD, aged 18–65
years, with Montgomery Asberg Depression Rating Scale
(MADRS) 26 and Clinical Global Impression Severity (CGI-S)
4, and with reported baseline duration of depressive episode of
12 weeks-1 year. The main cost-effectiveness (CEA) analysis was
conducted on the full analysis set (FAS), with all patients having
1 valid post-baseline health economic assessment. Additional
analyses were conducted on completers set (CS) with complete
follow-up data. Outcomes included Sheehan Disability Scale
(SDS), MADRS total score, treatment response (MADRS
decrease 50%) and remission (MADRS12), and health care
resource use and absenteeism from work evaluated by Health
Economic Assessment. Unit costs of health care services were
obtained from UK published standard sources. RESULTS: In the
main CEA analysis on FAS, escitalopram appears to be more
effective on the SDS scale (95% CI 0.10–3.74) and less costly
than duloxetine (95% CI -1.544 to -247). In additional analy-
ses on CS, patients on escitalopram had 49% lower total cost
compared to duloxetine (p = 0.002), with sick leave contributing
>73% of the total disease cost. Escitalopram was associated with
58% shorter sick leave duration compared to duloxetine
(p < 0.001). Patients with treatment response had 46% shorter
sick leave (p = 0.008), and those achieving remission, sick leave
was 53% shorter (0.002). CONCLUSION: Escitalopram domi-
nates duloxetine on the SDS scale, and is associated with signiﬁ-
cant cost savings compared to duloxetine. Treatment with
escitalopram may reduce sick leaves duration through improved
treatment response, and result in cost savings compared to
duloxetine. The results are in line with other economic studies
showing cost-saving with escitalopram compared to venlafaxine,
another SNRI.
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OBJECTIVES: Primary pulmonary hypertension (PPH) is a dis-
order with limited treatment options. Sildenaﬁl, an oral phos-
phodiestrase type-5 (PD-5) inhibitor and a pulmonary vasodilator,
is likely to be beneﬁcial in patients with primary pulmonary
hypertension,. we hypothesized that a single dose of Sildenaﬁl
could acutely reduce peak pulmonary artery pressure and improve
echocardiographic diameters of right heart. METHODS: We
studied 12 consecutive patients with PPH (10 patients with New
York Heart Association functional class 222, and 2 patients with
functional class22). After initial echocardiographic evaluation, a
100 mg oral single dose of Sildenaﬁl was added to previous
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